AbbVie's blood cancer drug meets late-stage trial goals
ABBV•Late-stage trial result
AbbVie ABBV.N said on Thursday its drug for a type of blood cancer has met the main goals of a late-stage trial.
Related News
CME Group Sr MD, General Counsel John Clifford Marchese files initial beneficial ownership statement
CME•
EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon
ELMT•
Copper recovers from 3-week low on dip-buying; LME stocks rise
XLB•
The Middleby Corporation <MIDD.O>: JP Morgan Raises to Overweight From Neutral; Raises Target Price to $147 From $141
MIDD•
AirAsia asks Ares for changes to terms of $200 million loan - Bloomberg News
ARES•